药物警戒监管干预的非预期影响评估:一项系统综述
该系统综述检索MEDLINE和EMBASE(2012年1月1日至2022年2月28日),纳入96篇调查欧洲药物警戒监管干预影响的研究。仅23篇(24%)报告了非预期影响评估,且2017年良好药物警戒实践指南更新后未见明显增加。
要点
- 仅24%的药物警戒监管干预研究评估了非预期影响。
- 非预期影响评估最常涉及口服降糖药、阿片类、抗抑郁药和抗精神病药。
- 2017年指南更新后对非预期影响的关注未见明显增加。
核心结论
- 仅四分之一的药物警戒监管干预研究出版物报告了非预期影响评估。
- 2017年良好药物警戒实践指南更新后,对非预期影响评估的关注未见明显增加。
研究设计与样本
- 系统综述,检索MEDLINE和EMBASE从2012年1月1日至2022年2月28日的文献。
- 纳入96篇调查欧洲药物警戒监管干预影响的出版物。
- 主要结局为报告非预期影响评估的出版物数量。
主要发现
- 96篇出版物中23篇(24%)调查了药物警戒监管干预的非预期影响。
- 评估非预期影响的研究最常涉及口服降糖药(n=6,26%)、阿片类(n=4,17%)、抗抑郁药(n=4,17%)和抗精神病药(n=3,13%)。
- 评估非预期影响的方法包括中断时间序列(n=10,43%)和描述性统计(无显著性检验n=2[9%],有显著性检验n=9[39%])。
- 非预期影响评估选择的结局包括其他药物使用(n=16,70%)、健康结局(n=8,35%)和行为改变(n=4,17%)。
- 多数出版物报告使用电子健康记录数据库(n=13,57%)或索赔数据库(n=13,57%),4篇(17%)使用登记数据库。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Studies assessing the impact of pharmacovigilance regulatory interventions often focus on the expected (or intended) outcomes, while any possible unintended impact may be overlooked. The update of the Good Pharmacovigilance Practice guideline in 2017 elaborated on impact assessment, emphasizing the need also to assess possible unintended impact. This systematic literature review investigated how often the unintended impact of regulatory interventions was considered in publications of studies investigating pharmacovigilance regulatory interventions in Europe. METHODS: We conducted a systematic review of the literature on MEDLINE and EMBASE from 1 January 2012 to 28 February 2022 to identify publications that investigated the impact of regulatory interventions in Europe. The primary outcome of the study was the number of publications reporting assessments of unintended impact. In addition, we studied the characteristics of these publications, including the type of outcomes assessed, the analytical methods applied and the type of data used. RESULTS: In total, 96 publications were included in the analysis. The unintended impact of pharmacovigilance regulatory interventions was investigated in 23 of 96 publications (24%). The drug classes most frequently studied in the publications assessing unintended impact of regulatory interventions were oral glucose-lowering drugs (n = 6, 26%), opioids (n = 4, 17%), antidepressants (n = 4, 17%) and antipsychotics (n = 3, 13%). The reported methods to assess the unintended impact were interrupted time series (n = 10, 43%) and descriptive statistics with or without significance testing (n = 2 [9%] and n = 9 [39%], respectively). The outcomes selected for unintended impact assessments included the use of other drugs (n = 16, 70%), health outcomes (n = 8, 35%) and behavioural changes (n = 4, 17%). Most of the publications reported on the use of electronic health record databases (n = 13, 57%) or claims databases (n = 13, 57%), while registries were used in 4 publications (17%). CONCLUSION: The unintended impact of pharmacovigilance regulatory interventions was reported in only a quarter of identified publications. There was no apparent increase in attention to unintended impact assessments after the update of the Good Pharmacovigilance Practice guidelines.
引用
- Lasys T, Santa-Ana-Tellez Y, Siiskonen SJ, et al. Unintended impact of pharmacovigilance regulatory interventions: A systematic review. Br J Clin Pharmacol. 2023. PMID: 37553757. doi:10.1111/bcp.15874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。